Clinical Trial

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours. The research treatment includes LM103 injection, IL-2 therapy, PD-1 therapy,fludarabine and cyclophosphamide.
Trial Details
NCT Number NCT06697665
Lead Sponsor Suzhou BlueHorse Therapeutics Co., Ltd.
Conditions Solid Cancer
Enrollment 10 participants
Start Date 2024-01-23
Primary Completion 2026-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-11-20